Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -46.61% is 1240% below its 5-year average of 4.09%, near the low end of its 5-year range (-50.09%–86.26%).
As of the fiscal period ended Tuesday, June 30, 2026. 24.86% below its 12-month average of -37.33%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
RETURN ON EQUITY (ROE)
-46.61%
RETURN ON EQUITY (ROE) AVG TTM
-37.33%
RETURN ON EQUITY (ROE) AVG 3Y
-35.64%
RETURN ON EQUITY (ROE) AVG 5Y
4.09%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-24.86%
CURRENT VS 3Y AVG
-30.75%
CURRENT VS 5Y AVG
-1239.55%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
-458.23%
vs the sector median at left
Moderna, Inc.
Market Cap
$55.68B
Return on Equity (ROE)
-46.61%
TTM Avg
-37.33%
3Y Avg
-35.64%
5Y Avg
4.09%
Market Cap
$56.32B
Return on Equity (ROE)
N/A
TTM Avg
-57.79%
3Y Avg
-38.31%
5Y Avg
2.19%
Market Cap
$49.93B
Return on Equity (ROE)
9.46%
TTM Avg
26.07%
3Y Avg
24.86%
5Y Avg
23.86%
Market Cap
$49.35B
Return on Equity (ROE)
3.85%
TTM Avg
6.60%
3Y Avg
6.50%
5Y Avg
6.42%
Market Cap
$48.40B
Return on Equity (ROE)
6.65%
TTM Avg
7.05%
3Y Avg
11.93%
5Y Avg
15.09%
Market Cap
$63.17B
Return on Equity (ROE)
86.03%
TTM Avg
168.34%
3Y Avg
-32.99%
5Y Avg
148.52%
Market Cap
$66.86B
Return on Equity (ROE)
14.71%
TTM Avg
10.21%
3Y Avg
8.16%
5Y Avg
6.40%
Market Cap
$42.81B
Return on Equity (ROE)
9.10%
TTM Avg
-6.34%
3Y Avg
-12.86%
5Y Avg
-14.53%
Market Cap
$42.67B
Return on Equity (ROE)
22.28%
TTM Avg
21.77%
3Y Avg
21.17%
5Y Avg
17.55%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Moderna, Inc. (MRNA) | $55.68B | -46.61% | -37.33% | -35.64% | 4.09% |
| Cardinal Health, Inc. (CAH)vs › | $56.32B | N/A | -57.79% | -38.31% | 2.19% |
| Edwards Lifesciences Corporation (EW)vs › | $49.93B | 9.46% | 26.07% | 24.86% | 23.86% |
| Becton, Dickinson and Company (BDX)vs › | $49.35B | 3.85% | 6.60% | 6.50% | 6.42% |
| Humana Inc. (HUM)vs › | $48.40B | 6.65% | 7.05% | 11.93% | 15.09% |
| Cencora, Inc. (COR)vs › | $63.17B | 86.03% | 168.34% | -32.99% | 148.52% |
| Boston Scientific Corporation (BSX)vs › | $66.86B | 14.71% | 10.21% | 8.16% | 6.40% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $42.81B | 9.10% | -6.34% | -12.86% | -14.53% |
| IQVIA Holdings Inc. (IQV)vs › | $42.67B | 22.28% | 21.77% | 21.17% | 17.55% |
| Agilent Technologies, Inc. (A)vs › | $41.48B | 19.56% | 20.59% | 21.51% | 20.54% |
ROE
-46.6%
ROA
-28.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -46.61% |
| 2026-03-31 | -43.12% |
| 2025-12-31 | -32.62% |
| 2025-09-30 | -33.40% |
| 2025-06-30 | -30.89% |
| 2025-03-31 | -33.35% |
| 2024-12-31 | -32.67% |
| 2024-09-30 | -18.65% |
| 2024-06-30 | -50.09% |
| 2024-03-31 | -46.56% |
| 2023-12-31 | -34.03% |
| 2023-09-30 | -25.76% |
| 2023-06-30 | 7.12% |
| 2023-03-31 | 25.36% |
| 2022-12-31 | 43.73% |
| 2022-09-30 | 65.39% |
| 2022-06-30 | 78.15% |
| 2022-03-31 | 85.73% |
| 2021-12-31 | 86.26% |
| 2021-09-30 | 69.75% |
| 2021-06-30 | 52.13% |
| 2021-03-31 | 15.59% |
| 2020-12-31 | -29.17% |
| 2020-09-30 | -21.66% |
| 2020-06-30 | -16.54% |
| 2020-03-31 | -30.82% |
| 2019-12-31 | -43.76% |
| 2019-09-30 | -42.52% |
| 2019-06-30 | -36.56% |
| 2019-03-31 | -30.77% |
| 2018-12-31 | -25.14% |
| 2018-09-30 | -26.13% |
| 2018-06-30 | -23.43% |
| 2018-03-31 | -41.37% |
| 2017-12-31 | -42.60% |
